Human Growth Hormone IV
“Some clinical studies have used intravenous (IV) infusion of recombinant Human Growth Hormone (HGH) in GH-deficient or hypopituitary adults and showed that IV administration leads to higher serum GH bioavailability than subcutaneous injection. Read More
However, short-term continuous IV infusion in healthy men suppressed the body’s own GH secretion (via feedback inhibition) and raised concerns about metabolic side-effects. Read More
Key caveats & medical consensus
Clinical IV-HGH has been studied only in limited, controlled settings — mostly for patients with GH deficiency, not for healthy individuals. Read More
Long-term safety, efficacy, and benefits (especially for “anti-aging,” athletic performance, or muscle-building in healthy adults) are not established. Leading institutions warn against off-label use due to potential risks (insulin resistance, edema, joint pain, etc.). Read More
Long-term safety, efficacy, and benefits (especially for “anti-aging,” athletic performance, or muscle-building in healthy adults) are not established. Leading institutions warn against off-label use due to potential risks (insulin resistance, edema, joint pain, etc.). Read More
In the U.S., HGH is legal only under physician supervision for approved medical conditions; off-label use (e.g. for anti-aging or muscle gains) is generally considered inappropriate and possibly illegal. Read More